Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527147 · ClinicalTrials.gov registry record · Phase 1
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
A Phase 1 study, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03527147 is a Phase 1 study that has completed, run by Acerta Pharma. The registered enrollment target is 30 participants.
The verdict
NCT03527147, a Phase 1 study, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).
Interventions
- DRUG Rituximab
- DRUG Acalabrutinib
- DRUG AZD6738
- DRUG Hu5F9-G4
- DRUG AZD9150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03527147
The ClinicalTrials.gov registry entry for NCT03527147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT03527147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03527147 about?
NCT03527147 is a clinical study titled "Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)". This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).
What is the current status of trial NCT03527147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-06-19. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03527147?
The interventions under investigation include: Rituximab (DRUG), Acalabrutinib (DRUG), AZD6738 (DRUG), Hu5F9-G4 (DRUG), AZD9150 (DRUG).
Who is sponsoring clinical trial NCT03527147?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.